Shannon John Patrick Jr reported tax withholding involving 36,645 shares of Xeris Biopharma Holdings, Inc. at $8.08 for −$296k on Aug 1, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
See Remarks
See Remarks
Filed Aug 21, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$296,091.60Shares × reported price
Shares traded
36,645Common Stock
Price per share
$8.08Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
2,898,933Direct
Trade date
Aug 1, 2026Tax withholding
Filed
Aug 21, 2026, 4:23 PM ET20-day reporting delay
Accession
0001867096-26-000073Code F · Transaction 30574
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 20 calendar days after the transaction date.

XERS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
XERS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −4.8%1w ago −4.3%1d ago −7%
Returns since7d −2.4%30d −5.8%90d180d1y

Footnotes in full

F1: Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.